<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775979</url>
  </required_header>
  <id_info>
    <org_study_id>FMASUMS730/2020/2021</org_study_id>
    <nct_id>NCT04775979</nct_id>
  </id_info>
  <brief_title>Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo</brief_title>
  <official_title>Efficacy and Safety of Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present work is to evaluate the efficacy and safety of diphenylcyclopropenone&#xD;
      (DPCP) as a depigmenting therapy in extensive Vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depigmentation protocol: (Aghaei et al, 2005)&#xD;
&#xD;
        -  Substance used: DPCP (FLUKA, Sigma-Aldrich, Saint Louis, MO (Missouri), USA) 98% pure&#xD;
           powder.&#xD;
&#xD;
        -  DPCP will be dissolved in acetone to obtain 2% solution.&#xD;
&#xD;
        -  DPCP solutions will be kept in dark colored bottles at 4ºC (degree Celsius).&#xD;
&#xD;
        -  Sequential dilution by acetone to yield 1%, 0.5%, 0.1%, 0.01%, 0.05 and 0.001%.&#xD;
&#xD;
        -  Sensitization by DPCP concentration 2% will be applied to an area 5×5 cm on the forearm&#xD;
&#xD;
        -  Two weeks following sensitization, treatment will be started by weekly applications of&#xD;
           incremental concentrations of DPCP (between 0.001% and 2%) adjusted according to the&#xD;
           patient's reactivity to the contact allergen. The aim will be to maintain mild contact&#xD;
           eczema and itch for about 48 hours after application. Patients will be instructed to&#xD;
           avoid direct sun exposure of the treated area and not to wash it for 48 hours after each&#xD;
           application.&#xD;
&#xD;
      Patient follow-up: Patients will come for sensitization at week 0, then after 2 weeks to look&#xD;
      for the allergic response, then weekly to reach the effective dose of DPCP. After reaching&#xD;
      the effective dose, patients will come weekly to apply DPCP and to look for depigmentation,&#xD;
      record possible side effects for 12 consecutive weeks.&#xD;
&#xD;
      Assessment of depigmentation:&#xD;
&#xD;
      For each treated area, response will be assessed as follows (van Geel et al., 2015):&#xD;
&#xD;
        -  Digital clinical pictures will be used to evaluate the capacity to induce depigmentation&#xD;
           and to assess the percentage of depigmentation per test area.&#xD;
&#xD;
        -  Treatment results will be subsequently classified according to a grading system from 0&#xD;
           to 6 (0 = no effect, 1 = &lt;25%; 2 = 25-49%; 3= 50-47%; 4= 50-74%; 5=90-99%; 6=100%),&#xD;
           corresponding to the grade of depigmentation.&#xD;
&#xD;
      Reporting any side effects: such as pain, erythema, blisters, erosions, hyperpigmentation,&#xD;
      scarring, appearance of depigmentation in distant sites and/or systemic manifestations&#xD;
      (Venkatesh et al,2018) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depigmentation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of depigmentation:&#xD;
For each treated area, response will be assessed as follows (van Geel et al., 2015):&#xD;
Digital clinical pictures will be used to evaluate the capacity to induce depigmentation and to assess the percentage of depigmentation per test area.&#xD;
Treatment results will be subsequently classified according to a grading system from 0 to 6 (0 = no effect, 1 = &lt;25%; 2 = 25-49%; 3= 50-47%; 4= 50-74%; 5=90-99%; 6=100%), corresponding to the grade of depigmentation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Diphenylcyclopropenone (DPCP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applying DPCP topically</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenylcyclopropenone (DPCP)</intervention_name>
    <description>Depigmenting agent</description>
    <arm_group_label>Diphenylcyclopropenone (DPCP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients of both genders ≥ 18 years.&#xD;
&#xD;
          2. Vitiligo universalis patients with cosmetically unacceptable residual pigmentation.&#xD;
&#xD;
          3. Extensive vitiligo vulgaris ≥ 50% body surface area (BSA) involvement with areas&#xD;
             recalcitrant to repigmentation on exposed skin with consequent psychological&#xD;
             impairment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children.&#xD;
&#xD;
          2. Early, localized, segmental or any vitiligo case responsive to repigmentation&#xD;
             treatment.&#xD;
&#xD;
          3. Pregnant and lactating females.&#xD;
&#xD;
          4. Patients with history of any malignancy.&#xD;
&#xD;
          5. Patients with active infectious or inflammatory dermatoses.&#xD;
&#xD;
          6. Patients with a history of hypertrophic scars or keloids.&#xD;
&#xD;
          7. Patients suffering from cardiac, hepatic or renal disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwa MA Abdallah</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rania M Elhusseiny</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maysoon Asem</last_name>
    <phone>01288335225</phone>
    <email>mayssoonaassem@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospitals faculty of medicine ain shams university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faculty of medicine Ain Shams University</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mayson</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

